Sellas Flags EU Biotech Act Talks<\/p>\n
Stergiou\u00a0said on LinkedIn<\/a> that Sellas was invited to the European Parliament to meet members and healthcare experts from the Public Health Committee, where the company was asked to share its thoughts, insights, and recommendations on the EU Biotech Act, drug approval processes, market access, health economics, and the region\u2019s competitiveness.<\/p>\n Stergiou called the discussions \u201cexceptionally constructive\u201d and said contributing to the EU Biotech Act dialogue was a \u201cmeaningful recognition\u201d of the work being done at Sellas. \u201cWe had the opportunity to draw direct relevance from our pipeline, sharing how our innovative approaches to cancer therapies intersect with the need for forward-thinking, supportive legislation,\u201d he said.\u00a0\u00a0<\/p>\n Stergiou said the talks also focused on how policy decisions could affect the speed at which therapies reach patients.\u00a0<\/p>\n Sellas AML Trial Nears Topline Readout<\/p>\n The policy talks come as investor attention remains centered on Sellas\u2019 ongoing Phase 3 Regal study evaluating GPS, an immunotherapy targeting the Wilms Tumor-1 antigen, as a maintenance treatment for patients with AML whose disease returned but later entered remission.<\/p>\n The event-driven trial is approaching the 80 overall-survival-event threshold required to trigger the topline analysis. The company previously said that 72 events had been recorded as of Dec. 26. Once the threshold is reached, Sellas plans to proceed with database lock, statistical analysis and unblinding of the study.<\/p>\n Stergiou has said that slower accumulation of survival events in oncology trials can sometimes indicate patients are living longer than initially expected. He also reiterated recently that his \u201cconviction in the REGAL trial\u2019s prospects and ultimate commercial potential remains as steadfast today as it was day 1.\u201d<\/p>\n Sellas Seeks 20M Share Plan Boost<\/p>\n Separately, Sellas has asked shareholders to approve an expansion of its 2023 Amended and Restated Equity Incentive Plan by\u00a020 million shares<\/a>, aiming to replenish its stock-based compensation pool. The company said only 7,991 shares remained available for future awards as of mid-April. The approval would also allow a previously approved grant of 1.1 million restricted stock units to Stergiou to take effect.<\/p>\n As of April 15, Sellas reported 2.64 million stock options and 2.26 million restricted stock units outstanding, with total equity overhang representing about 2.6% of shares outstanding.<\/p>\n Beyond Regal, the company has pointed to 2026 as a key year for its CDK9 inhibitor SLS009, with clinical updates and topline data expected from ongoing Phase 2 studies. Preclinical findings showed that the therapy triggered programmed cell death in leukemia cells and remained active in AML associated with ASXL1 and TP53 mutations.<\/p>\n How Do Retail Traders Feel About SLS?<\/p>\n On Stocktwits, retail sentiment for SLS was \u2018neutral\u2019 amid over a 200% jump in 24-hour message volumes.<\/p>\n One user\u00a0noted<\/a> Stergiou\u2019s LinkedIn post and said, \u201cThat is the footprint of a company stepping onto a much bigger stage. Add REGAL in the decisive stretch, SLS009 gaining weight, and the CEO speaking with total conviction, and the picture gets louder every day.\u201d<\/p>\n Another user\u00a0said<\/a>, \u201cMost unusual for a small Biotech company to address the EU Public Health Committee on Policy. Strong signal to institutional investors.\u201d<\/p>\n SLS stock has surged 189% over the past year.\u00a0<\/p>\n For updates and corrections, email newsroom[at]stocktwits[dot]com.<\/p>\n Read Next:\u00a0PLTR Reports Largest Quarterly Revenue Jump, Quadrupled Profits, But Valuation Concerns Persist\u00a0<\/a><\/p>\n![\"sls](\"https:\/\/www.europesays.com\/europe\/wp-content\/uploads\/2026\/05\/sls_ss_png_8a78d55d93.webp\")
SLS sentiment and message volume as of May 4 | Source: Stocktwits<\/p>\n
![\"Follow](\"https:\/\/chunks-prd.stocktwits-cdn.com\/_next\/static\/media\/google-news-icon.d9c2bfd1.svg\"\/){kind=icon}
<\/a><\/p>\n